ViiV Healthcare (/ˈviːv/ VEEV) is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS.

[2] According to The Financial Times, the company's co-ownership structure may change depending on the achievement of certain milestones.

[1] ViiV Healthcare's products have a market share of approximately 32% of the global HIV therapy market, making it the second-largest healthcare company in the sector, after Gilead Sciences.

[3] ViiV Healthcare's global headquarters are in London in the United Kingdom, and the company has sites in a number of other countries including the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.

[7][8] In March 2020, ViiV Healthcare announced the initiation of a study in partnership with University of South Carolina's Ryan White Program to determine the effectiveness of ride-sharing services in improving access to care for people living with HIV.